You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

platinum sensitive primary peritoneal cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab)

Recruiting
  • Ovarian Cancer
  • +2 more
  • New Orleans, Louisiana
  • +3 more
Dec 16, 2022

High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine, Carboplatin)

Not yet recruiting
  • High Grade Ovarian Cancer
  • +2 more
  • (no location specified)
Jul 11, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Active, not recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +11 more
  • Aldesleukin
  • +3 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 13, 2022

Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor Trial

Active, not recruiting
  • Fallopian Tube Endometrioid Tumor
  • +13 more
  • Orange, California
  • +19 more
Jan 10, 2023

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Australia (ATX-101 + Carboplatin + Pegylated

Recruiting
  • Ovarian Cancer
  • +3 more
  • ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)
  • Blacktown, New South Wales, Australia
  • +5 more
Nov 9, 2022

Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma Trial in United

Active, not recruiting
  • Metastatic Fallopian Tube Carcinoma
  • +11 more
  • Phoenix, Arizona
  • +13 more
Dec 2, 2022

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma Trial in Buffalo, New York (biological, other, drug)

Active, not recruiting
Has Results
  • BRCA1 Gene Mutation
  • +5 more
  • Durvalumab
  • +3 more
  • Buffalo, New York
  • +1 more
Jan 20, 2023

Ovarian Cancer, Fallopian Tubes Cancer, Peritoneal Cancer Trial in United States (Secondary Cytoreductive Surgery, Carboplatin

Active, not recruiting
  • Ovarian Cancer
  • +2 more
  • Secondary Cytoreductive Surgery
  • +2 more
  • Hartford, Connecticut
  • +10 more
Feb 23, 2022

Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma Trial in United States (Pazopanib, Doxil)

Terminated
Has Results
  • Ovarian Cancer
  • +2 more
  • Fort Myers, Florida
  • +3 more
Oct 4, 2021

Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma Trial (DCVAC/OvCa, DCVAC/OvCa )

Withdrawn
  • Ovarian Cancer
  • +2 more
  • DCVAC/OvCa
  • DCVAC/OvCa placebo
  • (no location specified)
Dec 6, 2021

Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma Trial in United States (biological, other,

Recruiting
  • Cervical Adenocarcinoma
  • +47 more
  • Bevacizumab
  • +3 more
  • Phoenix, Arizona
  • +3 more
Dec 5, 2022

Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in

Not yet recruiting
  • Ovarian Clear Cell Adenocarcinoma
  • +14 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +4 more
  • Buffalo, New York
  • +1 more
Dec 16, 2022

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Japan (Niraparib)

Active, not recruiting
Has Results
  • Ovarian Cancer
  • +2 more
  • Nagoya, Aichi, Japan
  • +26 more
Feb 7, 2022

Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma Trial in

Recruiting
  • Fallopian Tube Carcinosarcoma
  • +28 more
  • Pegylated Liposomal Doxorubicin Hydrochloride
  • Peposertib
  • Aurora, Colorado
  • +7 more
Sep 2, 2022

High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Cambridge (Upifitimab rilsodotin,

Recruiting
  • High Grade Serous Ovarian Cancer
  • +2 more
  • Upifitimab rilsodotin
  • Placebo
  • Phoenix, Arizona
  • +40 more
Jan 25, 2023

Peritoneal Carcinomatosis, Ovarian Cancer Trial in Belgium, Germany, Norway (Radspherin)

Recruiting
  • Peritoneal Carcinomatosis
  • Ovarian Cancer
  • Leuven, Belgium
  • +3 more
Sep 3, 2021

Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Bronx, New York

Completed
Has Results
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Bronx, New York
  • +2 more
Oct 18, 2021

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Oklahoma City (Paclitaxel, Cisplatin IP)

Terminated
Has Results
  • Ovarian Cancer
  • +3 more
  • Paclitaxel, Cisplatin IP
  • Oklahoma City, Oklahoma
    University of Oklahoma Health Sciences Center
Apr 28, 2021

Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Worldwide (Mirvetuximab soravtansine)

Recruiting
  • Ovarian Cancer
  • +2 more
  • Mirvetuximab soravtansine
  • Anchorage, Alaska
  • +55 more
Jul 25, 2022

PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Recruiting
  • PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Dec 4, 2022

Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Aurora (Mirvetuximab Soravtansine, Olaparib)

Not yet recruiting
  • Ovary Cancer
  • +2 more
  • Aurora, Colorado
    University of Colorado Hospital
May 30, 2023

Platinum-sensitive Relapsed Ovarian Cancer Trial in China (ZL-2306(nirapairb), Placebos)

Active, not recruiting
  • Platinum-sensitive Relapsed Ovarian Cancer
  • Guangzhou, Guangdong, China
  • +26 more
Oct 14, 2021

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Germany, Italy (Niraparib)

Recruiting
  • Ovarian Cancer
  • +2 more
  • Berlin, Germany
  • +11 more
Sep 15, 2021

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, PARP Inhibitor Trial in Pittsburgh

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +3 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 8, 2022

Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer Trial (Luveltamab tazevibulin, Pegfilgrastim)

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • (no location specified)
May 12, 2023